We are live on ! Find out more
SI

Sofinnova Investments Portfolio holdings

AUM $2.63B
1-Year Est. Return 117.41%
This Fund
S&P 500
This Quarter Est. Return
+2.68%
1 Year Est. Return
+117.41%
3 Year Est. Return
+428.82%
5 Year Est. Return
+748.21%
10 Year Est. Return
–
AUM
$2.63B
AUM Growth
+$312M
Cap. Flow
+$315M
Cap. Flow %
11.96%
Top 10 Hldgs %
49.1%
Holding
89
New
29
Increased
24
Reduced
12
Closed
15

Top Buys

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$69M
2
BIIB icon
Biogen
BIIB
+$42.3M
3
AXSM icon
Axsome Therapeutics
AXSM
+$34.6M
4
ALC icon
Alcon
ALC
+$31.7M
5
INSM icon
Insmed
INSM
+$29.1M

Top Sells

Rank Stock Value
1
VRTX icon
Vertex Pharmaceuticals
VRTX
+$74.6M
2
ABBV icon
AbbVie
ABBV
+$72.6M
3
ISRG icon
Intuitive Surgical
ISRG
+$71.9M
4
AZN icon
AstraZeneca
AZN
+$69.4M
5
LLY icon
Eli Lilly
LLY
+$66.3M

Sector Composition

Rank Sector Weight
1 Healthcare 75.86%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
REPL icon
51
CALL
Replimune Group
REPL
$814M
$7.77M 0.3%
+1,015,400
New +$7.76M
RARE icon
52
CALL
Ultragenyx Pharmaceutical
RARE
$2.65B
$7.33M 0.28%
+350,000
New +$7.88M
AXGN icon
53
Axogen
AXGN
$2.1B
$6.98M 0.27%
+210,665
New +$6.85M
DFTX
54
Definium Therapeutics
DFTX
$5.73B
$6.5M 0.25%
+344,166
New +$5.84M
CYTK icon
55
Cytokinetics
CYTK
$11B
$6.05M 0.23%
+91,791
New +$5.83M
IRON icon
56
Disc Medicine
IRON
$2.83B
$5.01M 0.19%
78,320
-32,690
-29% -$2.27M
MANE
57
Veradermics Inc
MANE
$4.58B
$4.63M 0.18%
+73,315
New +$3.7M
HRMY icon
58
Harmony Biosciences
HRMY
$2.04B
$4.28M 0.16%
+152,695
New +$5.01M
PCVX icon
59
Vaxcyte
PCVX
$7.89B
$2.94M 0.11%
+50,600
New +$2.75M
CMPX icon
60
CALL
Compass Therapeutics
CMPX
$373M
$2.65M 0.1%
+500,000
New +$2.89M
MIRM icon
61
Mirum Pharmaceuticals
MIRM
$6.89B
$2.55M 0.1%
27,591
+4,491
+19% +$422K
NXTC icon
62
NextCure
NXTC
$17.3M
$2.38M 0.09%
222,654
– –
SVRA icon
63
Savara
SVRA
$1.13B
$1.99M 0.08%
364,763
+59,993
+20% +$334K
ESTA icon
64
Establishment Labs
ESTA
$2.72B
$1.93M 0.07%
33,930
+5,564
+20% +$380K
ACAD icon
65
Acadia Pharmaceuticals
ACAD
$4.25B
$1.75M 0.07%
78,551
+12,984
+20% +$310K
TENX icon
66
Tenax Therapeutics
TENX
$385M
$1.67M 0.06%
+104,400
New +$1.41M
JBIO
67
Jade Biosciences
JBIO
$1.22B
$1.51M 0.06%
107,391
– –
WVE icon
68
Wave Life Sciences
WVE
$1.12B
$1.37M 0.05%
189,253
+31,071
+20% +$405K
SEPN
69
Septerna Inc
SEPN
$1.49B
$1.14M 0.04%
+47,506
New +$1.25M
OKUR
70
OnKure Therapeutics
OKUR
$166M
$587K 0.02%
+141,700
New +$437K
BOLT icon
71
Bolt Biotherapeutics
BOLT
$7.36M
$556K 0.02%
137,721
– –
SLNO
72
DELISTED
Soleno Therapeutics
SLNO
$492K 0.02%
14,689
+2,275
+18% +$89.2K
IMA
73
ImageneBio Inc
IMA
$63.1M
$159K 0.01%
31,884
– –
ZYME icon
74
Zymeworks
ZYME
$1.68B
$40.3K ﹤0.01%
+1,610
New +$38.1K
ABBV icon
75
AbbVie
ABBV
$458B
– –
-317,783
Closed -$72.6M
1 2
3
4

Similar funds

WWM
Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return
ACI
Amazon.com Inc Seattle, Washington $2.63B AUM 20.53% 1-Year Est. Return
LOAMS
Lombard Odier Asset Management (Switzerland) Petit-Lancy, Switzerland $2.63B AUM 31.52% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
WCA
Waratah Capital Advisors Toronto, Ontario, Canada $2.63B AUM 76.33% 1-Year Est. Return
ACM
Advance Capital Management Southfield, Michigan $2.64B AUM 13.57% 1-Year Est. Return
NIG
NFJ Investment Group Dallas, Texas $2.64B AUM 23.86% 1-Year Est. Return
WBG
Wharton Business Group Malvern, Pennsylvania $2.65B AUM 20.73% 1-Year Est. Return

Sofinnova Investments's Q1 2026 Portfolio in Review

As of Q1 2026, Sofinnova Investments held 89 positions worth $2.63B, up 13% from $2.32B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Sofinnova Investments deployed $315M of net new capital in Q1 2026, opening 29 new positions and adding to 24 existing holdings. Its largest new stake was Biogen: 229,521 shares worth $42.1M.

By sector, the portfolio is most concentrated in Healthcare at 76% of assets, down from 100% a quarter earlier.

On the sell side, the largest reduction was AstraZeneca, an estimated $69.4M trimmed.

  • Sofinnova Investments's largest Q1 2026 buy was Biogen: 229,521 shares worth $42.1M.
  • Sofinnova Investments added most to Ultragenyx Pharmaceutical in Q1 2026, an estimated $69M increase.
  • Sofinnova Investments's biggest Q1 2026 reduction was AstraZeneca, cutting an estimated $69.4M.
  • Sofinnova Investments fully exited Vertex Pharmaceuticals in Q1 2026, selling an estimated $74.6M.
  • Sofinnova Investments's ten largest holdings make up 49% of its $2.63B portfolio in Q1 2026.
  • Sofinnova Investments opened 29 new positions and closed 15 in Q1 2026.
  • Sofinnova Investments's portfolio value rose 13% quarter-over-quarter to $2.63B.

Based on Sofinnova Investments's 13F filing for Q1 2026, filed 15 May 2026.